Novo Nordisk Faces Board Overhaul Amid Strategic Shifts and Market Pressures
Leadership Turmoil at Europe’s Former Most Valuable Company Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs Ozempic and Wegovy,…
Leadership Turmoil at Europe’s Former Most Valuable Company Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs Ozempic and Wegovy,…
Researchers have pinpointed a third genetic mutation responsible for a rare form of diabetes appearing in infants under six months. The discovery reveals how the TMEM167A gene disrupts insulin production while affecting neurological development. This breakthrough provides new avenues for understanding diabetes mechanisms and potential treatments.
International scientists have identified a previously unknown genetic driver behind a rare form of diabetes that exclusively affects newborn infants, according to recent research reports. The study reveals that specific mutations in the TMEM167A gene can disable and ultimately destroy insulin-producing cells, providing crucial insights into both rare and common forms of diabetes.